In particular, the combination of augmenting both CD8 T cells and NK cells means that tumours that down-regulate MHC class I to avoid CD8 T cell mediated lysis, lose an important inhibitory signal for NK cells, and thus render themselves susceptible to NK cell killing. Here, CD8A is linked to neoplasm.